BSVL gets nod for trial of Ulinastatin for COVID-19

Study for use with ARDS patients

June 09, 2020 10:24 pm | Updated 11:06 pm IST - MUMBAI

Bharat Serums and Vaccines Ltd. (BSVL) has received approval from DCGI to conduct phase III clinical study on Ulinastatin for mild to moderate Acute Respiratory Distress Syndrome (ARDS) patients with COVID-19, the company said in a statement.

Clinical trial is expected to start at hospitals shortly. The mortality risk is higher when an individual with COVID-19 infection develops ARDS and pneumonia. ARDS causes dry cough, heavy breathing, breathing difficulties and increased heart rate.

In such a case, Ulinastatin can be administered as a remedy to combat the underlying inflammatory condition related to ARDS in COVID-19 patients.

Sanjiv Navangul, MD and CEO, BSVL said, “Identifying effective antiviral agents and therapies to combat underlying pathology of COVID-19 is the need of the hour.”

“As one of the leading biopharmaceutical companies in India we are channeling our efforts towards the ongoing fight against the COVID-19 pandemic,” he added.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.